Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612963 · ClinicalTrials.gov registry record
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
A clinical trial, sponsored by Biomedical Development Corporation.
- Completed
- Registry status
- 23
- Enrollment target
NCT00612963: Completed study, sponsored by Biomedical Development Corporation.
NCT00612963 is a clinical trial that has completed, run by Biomedical Development Corporation. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00612963 has completed, sponsored by Biomedical Development Corporation.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received radiation therapy for head and neck cancer, or patients positive for HIV/AIDS or are transplant patients.
Interventions
- DRUG Frio Oral Rinse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-05 |
What the finished NCT00612963 record still lists
NCT00612963 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Frio Oral Rinse is the first listed.
NCT00612963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00612963 about?
NCT00612963 is a clinical study titled "Novel Rinse to Treat in Oral Candidiasis in Cancer Patients". The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received radiation therapy for head and neck cancer, or patients positive for HIV/AIDS...
What is the current status of trial NCT00612963?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2007-04. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00612963?
The interventions under investigation include: Frio Oral Rinse (DRUG).
Who is sponsoring clinical trial NCT00612963?
This trial is sponsored by Biomedical Development Corporation, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia